Bayer To Retain Kogenate Line Following Plasma Unit Spin-Off
This article was originally published in The Pink Sheet Daily
Executive Summary
Company divests plasma products business to NPS BioTherapeutics under a $590 mil. agreement. Bayer will receive 10% equity in NPS, a new corporation formed by Cerebus Capital Management and Ampersand Ventures.